CN104274497B - Application of Taiwan cordyceps extract in preparing anti-respiratory virus medicine - Google Patents
Application of Taiwan cordyceps extract in preparing anti-respiratory virus medicine Download PDFInfo
- Publication number
- CN104274497B CN104274497B CN201310288100.4A CN201310288100A CN104274497B CN 104274497 B CN104274497 B CN 104274497B CN 201310288100 A CN201310288100 A CN 201310288100A CN 104274497 B CN104274497 B CN 104274497B
- Authority
- CN
- China
- Prior art keywords
- taiwan cordyceps
- taiwan
- extract
- cordyceps
- respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000190633 Cordyceps Species 0.000 title claims abstract description 40
- 239000000284 extract Substances 0.000 title claims abstract description 34
- 241000700605 Viruses Species 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 230000003097 anti-respiratory effect Effects 0.000 title claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 14
- 241000254173 Coleoptera Species 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000000241 respiratory effect Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 5
- 208000035473 Communicable disease Diseases 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000012258 culturing Methods 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 9
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 8
- 241000209219 Hordeum Species 0.000 description 7
- 235000007340 Hordeum vulgare Nutrition 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000002832 anti-viral assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 201000005264 laryngeal carcinoma Diseases 0.000 description 3
- 231100000028 nontoxic concentration Toxicity 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000746891 Ophiocordyceps formosana Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960000402 palivizumab Drugs 0.000 description 2
- GUEIZVNYDFNHJU-UHFFFAOYSA-N quinizarin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=CC=C2O GUEIZVNYDFNHJU-UHFFFAOYSA-N 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940036185 synagis Drugs 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses application of Taiwan cordyceps extract in preparing a medicament for resisting respiratory viruses, and experiments prove that the Taiwan cordyceps extract has a remarkable inhibiting effect on the respiratory viruses, which prompts that the Taiwan cordyceps extract has potential application value in the field of treating respiratory virus infectious diseases and has great significance in treating the respiratory virus infectious diseases. The invention provides experimental basis for clinical application of Taiwan cordyceps in treating virus infectious diseases, provides certain guiding significance for developing anti-respiratory virus medicines, and has important reference value.
Description
Technical Field
The invention relates to an application of Taiwan cordyceps extract in preparing a respiratory virus resisting medicine.
Background
Taiwan Cordyceps (Cordyceps formosana Kobayasi & Shimizu) was first discovered in 7 months in 1976 by Queensland of Japan and was formally named as Taiwan Cordyceps (Cordyceps formosana Kobayasi & Shimizu) in 1981, and the mainland China also reported that Anhui Oncao discovered Taiwan Cordyceps in Huangshan mountain of the mainland China in 2002. Research and development personnel of the technical part limited of Taiwan Murray of China in 7 months in 2009 collected Taiwan cordyceps sinensis in Taiwan creek of China, separated and identified as Taiwan cordyceps sinensis by related experts. The applicant established a research topic group of Taiwan cordyceps, conducted intensive research on Taiwan cordyceps, succeeded in artificial fermentation of Taiwan cordyceps species, successfully grown fruiting bodies in artificial culture media, and artificially cultured Taiwan cordyceps using live beetle larvae of the order Coleoptera (e.g., barley worm larvae).
The Taiwan cordyceps sinensis contains more bioactive components, such as adenosine, mannitol, cordycepin, quinizarin, oleic acid, ergosterol, stearic acid, palmitic acid and other chemical components. Research shows that the Taiwan cordyceps sinensis can obviously enhance the immune function of organisms; active substances with strong free radical scavenging effect; has strong antitumor activity, and also has antibacterial, antiinflammatory, and antioxidant effects.
Respiratory Syncytial Virus (RSV) is a common pathogen worldwide causing bronchiolitis and pneumonia in infants and young children, with almost all children experiencing 1 or more infection at age 2, with peak ages of 2 to 8 months. Is the primary cause of lower respiratory tract infection of infants and young children and also the primary cause of hospitalization of young children due to respiratory tract diseases, and multiple studies also show that the serious RSV infection of infants is a high-risk factor for the subsequent development of asthma, and the severity of the RSV infection is far more than that of other microbial pathogens. RSV infection has also been found to be an important etiological agent in immunosuppressed adults and the elderly.
There is currently a lack of specific and effective treatments for RSV infection. The antiviral drug Ribavirin (Ribavirin) is the only chemotherapy drug approved by the FDA at present and used for preventing and treating RSV infection, but the drug can cause side effects such as headache, leukopenia, irreversible anemia, serum bilirubin increase and the like due to myelocytotoxicity, and the clinical application of the drug is limited, and the drug is only strictly used for children at high risk and serious illness, and the curative effect of the drug is controversial in recent years. Although the human monoclonal antibody palivizumab (synagis) and intravenous immunoglobulin (RSV-IGIV) have been registered for use and have good curative effect, due to the problems of treatment cost and safety of serum products, careful consideration is still needed in the prevention and treatment of RSV infection, and the monoclonal antibody palivizumab (synagis) and intravenous immunoglobulin (RSV-IGIV) cannot be generally applied to clinic. To date, no vaccine has been clinically used to prevent RSV infection. Therefore, the development of a medicament for preventing and treating RSV infection with reliable efficacy and small toxic and side effects is still one of the important problems to be solved internationally at present.
The applicant researches and discovers that the Taiwan cordyceps extract has good anti-RSV effect, and related research reports and patent documents of the anti-RSV effect of the Taiwan cordyceps extract are not found at present.
Disclosure of Invention
The invention aims to relate to application of a Taiwan cordyceps extract in preparing a medicine for resisting respiratory viruses.
The purpose of the invention is realized by the following technical scheme:
the invention provides an application of Taiwan cordyceps extract in preparing a medicine for resisting respiratory viruses.
The Taiwan cordyceps extract is prepared by using artificially fermented mycelium of Taiwan cordyceps, growing sporocarp in an artificial culture medium or artificially culturing Taiwan cordyceps by using larvae of beetles of Coleoptera, extracting with ethanol, and performing rotary evaporation to obtain paste. Drying the obtained extract, adding conventional adjuvants, and making into pharmaceutically acceptable conventional dosage forms such as capsule, tablet, granule, gel, sustained release agent, and oral liquid by conventional preparation method.
The Taiwan cordyceps extract is obtained by extracting artificially fermented mycelium of Taiwan cordyceps, growing sporocarp in an artificial culture medium or artificially culturing Taiwan cordyceps by utilizing larvae of beetles of Coleoptera through ethanol, and has good effect of inhibiting the activity of respiratory syncytial virus shown by an anti-respiratory syncytial virus activity experiment.
The Taiwan cordyceps extract provided by the invention is preferably extracted by ethanol with the content of 10% -90%, and more preferably by ethanol with the content of 20% -80%.
The use according to the invention, wherein the dose of the anti-respiratory virus medicament administered is between 1.5 μ g/mL and 50.0 μ g/mL.
Detailed Description
The technical means adopted by the invention to achieve the preset invention purpose are further described below by matching with the preferred embodiment of the invention.
Experimental example 1: experiment on the activity of artificially fermented mycelium extract of Taiwan cordyceps sinensis for inhibiting respiratory syncytial virus.
1. Cytotoxicity assays
HEp-2 cells (human laryngeal carcinoma epithelial cells) were inoculated into 96-well cell culture plates and placed at 37 ℃ with 5% CO2Culturing in an incubator, removing culture solution after the cells grow into a monolayer, washing twice with PBS, adding 0.1mL of test solution diluted in half with maintenance solution, and setting 0.1mL of maintenance solution as blank control. Continuously placing at 37 ℃ with 5% CO2Culturing in incubator for 2-5 days, observing cytopathic condition including cell monolayer detachment, rounding, shrinkage, formation of granule and vacuole in cytoplasm under microscope every day, recording result, and calculating semi-Toxic Concentration (TC)50)。
2. Antiviral assay
HEp-2 cells were cultured as above, the culture medium was removed, washed with PBS, and 0.1mL (100 TCID) was added500.1mL virus) and 0.1mL of maximum cell nontoxic concentration (which means the maximum concentration of a test article which is observed and detected under a light microscope and does not generate toxicity on cells) as a test article solution after half-and-half dilution, and a maintenance solution is used as a blank control. The cells were placed at 37 ℃ in 5% CO2Culturing in an incubator for 2 to 5 days. The cytopathic condition caused by the virus is detected under the mirror and recorded. Ribavirin was used as the positive control drug.
Calculate half maximal inhibitory concentration (EC)50) And therapeutic index TI ═ TC50/EC50。
3. Respiratory syncytial virus resisting activity of artificial fermentation mycelium extract of Taiwan cordyceps sinensis
Extract of artificial fermentation mycelium of Taiwan cordyceps sinensis: extracting artificially fermented mycelium of Taiwan cordyceps sinensis with 20% ethanol, and rotary evaporating to obtain paste, i.e. the artificially fermented mycelium extract of Taiwan cordyceps sinensis.
Specific results are shown in Table 1
TABLE 1 inhibition of respiratory syncytial virus by Taiwan cordyceps sinensis artificial fermentation mycelium extract
Experimental example 2: experiment on the activity of sporophore extract of Taiwan cordyceps for inhibiting respiratory syncytial virus.
1. Cytotoxicity assays
HEp-2 cells (human laryngeal carcinoma epithelial cells) were inoculated into 96-well cell culture plates and placed at 37 ℃ with 5% CO2Culturing in an incubator, removing culture solution after the cells grow into a monolayer, washing twice with PBS, adding 0.1mL of test solution diluted in half with maintenance solution, and setting 0.1mL of maintenance solution as blank control. Continuously standing at 37 deg.C for 5% CO2Culturing in incubator for 2-5 days, observing cytopathic condition including cell monolayer detachment, rounding, shrinkage, formation of granule and vacuole in cytoplasm under microscope every day, recording result, and calculating semi-Toxic Concentration (TC)50)。
2. Antiviral assay
HEp-2 cell culture method as above, remove culture medium, wash with PBS, add 0.1mL (100 TCID)500.1mL virus) and 0.1mL of maximum cell nontoxic concentration (which means the maximum concentration of a test article which is observed and detected under a light microscope and does not generate toxicity on cells) as a test article solution after half-and-half dilution, and a maintenance solution is used as a blank control. The cells were placed at 37 ℃ in 5% CO2Culturing in an incubator for 2 to 5 days. The cytopathic condition caused by the virus is detected under the mirror and recorded. Ribavirin was used as the positive control drug.
Calculate half maximal inhibitory concentration (EC)50) And therapeutic index TI ═ TC50/EC50。
3. Respiratory syncytial virus resisting activity of Taiwan cordyceps sporophore extract
Extract of fruiting body of Taiwan cordyceps sinensis: the fruiting body of Taiwan cordyceps sinensis grown on the artificial culture medium is extracted by 50% ethanol, and is rotated and evaporated to obtain a paste, namely the fruiting body extract of Taiwan cordyceps sinensis.
Specific results are shown in Table 2
TABLE 2 inhibitory Effect of Taiwan Cordyceps exicus fruiting body extract on respiratory syncytial Virus
Experimental example 3: experiments on the inhibition of respiratory syncytial virus activity using extracts of artificially cultured Taiwan cordyceps (worm, grass conjugate) from larvae of beetles of the order Coleoptera (e.g., barley worm larvae).
1. Cytotoxicity assays
HEp-2 cells (human laryngeal carcinoma epithelial cells) were inoculated into 96-well cell culture plates and placed at 37 ℃ with 5% CO2Culturing in an incubator, removing culture solution after the cells grow into a monolayer, washing twice with PBS, adding 0.1mL of test solution diluted in half with maintenance solution, and setting 0.1mL of maintenance solution as blank control. Continuously standing at 37 deg.C for 5% CO2Culturing in incubator for 2-5 days, observing cytopathic conditions including cell monolayer detachment, rounding, shrinkage, formation of granule and vacuole in cytoplasm under microscope every day, recording result, and calculatingsemi-Toxic Concentration (TC)50)。
2. Antiviral assay
HEp-2 cells were cultured as above, the culture medium was removed, washed with PBS, and 0.1mL (100 TCID) was added500.1mL virus) and 0.1mL of maximum cell nontoxic concentration (which means the maximum concentration of a test article which is observed and detected under a light microscope and does not generate toxicity on cells) as a test article solution after half-and-half dilution, and a maintenance solution is used as a blank control. The cells were placed at 37 ℃ in 5% CO2Culturing in an incubator for 2 to 5 days. The cytopathic condition caused by the virus is detected under the mirror and recorded. Ribavirin was used as the positive control drug.
Calculate half maximal inhibitory concentration (EC)50) And therapeutic index TI ═ TC50/EC50。
3. Anti-respiratory syncytial virus activity of barley insect Taiwan cordyceps sinensis extract
Barley insect Taiwan cordyceps sinensis extract: extracting the barley Taiwan cordyceps (worm and grass combination) with 80% ethanol, and performing rotary evaporation to obtain a paste, namely the barley Taiwan cordyceps extract.
Specific results are shown in Table 3
TABLE 3 inhibitory Effect of barley Worm Taiwan Cordyceps extract on respiratory syncytial Virus
The experimental results are the same after repeated for many times, and the Taiwan cordyceps extract has obvious effect of resisting Respiratory Syncytial Virus (RSV) and can be used for development and application of medicaments.
Although the present invention has been described with reference to a preferred embodiment, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (5)
1. Taiwan cordyceps sinensisCordyceps formosana Kobayasi & ShimizuThe extract is used for preparing a medicine for resisting respiratory syncytial virus, wherein the Taiwan cordyceps extract is extracted by ethanol with the content of 10 percent ~ 90 percent.
2. The use according to claim 1, wherein the Taiwan cordyceps is Taiwan cordyceps cultured artificially with artificially fermented mycelia of Taiwan cordyceps, growing fruit bodies using an artificial culture medium, or using larvae of beetles of the order Coleoptera.
3. The use of claim 1, wherein the extract of Taiwan cordyceps is extracted with ethanol having a content of 20% ~ 80%.
4. The use of claim 2, wherein the extract of Taiwan cordyceps is extracted with ethanol having a content of 20% ~ 80%.
5. The use according to claim 1, wherein the anti-respiratory virus medicament is a capsule, a tablet, a granule, a gel or an oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310288100.4A CN104274497B (en) | 2013-07-10 | 2013-07-10 | Application of Taiwan cordyceps extract in preparing anti-respiratory virus medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310288100.4A CN104274497B (en) | 2013-07-10 | 2013-07-10 | Application of Taiwan cordyceps extract in preparing anti-respiratory virus medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104274497A CN104274497A (en) | 2015-01-14 |
| CN104274497B true CN104274497B (en) | 2019-12-20 |
Family
ID=52250159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310288100.4A Expired - Fee Related CN104274497B (en) | 2013-07-10 | 2013-07-10 | Application of Taiwan cordyceps extract in preparing anti-respiratory virus medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104274497B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1112415A (en) * | 1994-05-21 | 1995-11-29 | 汪景山 | Cordyceps Cosmetics |
| CN101018869A (en) * | 2004-07-16 | 2007-08-15 | 药用菌类公司 | Immune modulating compounds from fungi |
-
2013
- 2013-07-10 CN CN201310288100.4A patent/CN104274497B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1112415A (en) * | 1994-05-21 | 1995-11-29 | 汪景山 | Cordyceps Cosmetics |
| CN101018869A (en) * | 2004-07-16 | 2007-08-15 | 药用菌类公司 | Immune modulating compounds from fungi |
Non-Patent Citations (1)
| Title |
|---|
| 人工培植虫草预防儿童反复呼吸道感染的效果观察;江爱英等;《中国医药指南》;20130620;第11卷(第17期);第525-526页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104274497A (en) | 2015-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8765138B2 (en) | Antiviral and antibacterial activity from medicinal mushrooms | |
| US20060171958A1 (en) | Antiviral activity from medicinal mushrooms | |
| US20140105928A1 (en) | Antiviral and antibacterial activity from medicinal mushrooms | |
| US20080131529A1 (en) | Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof | |
| US20110008384A1 (en) | Antiviral activity from medicinal mushrooms | |
| CN102688332B (en) | A kind of Chinese medicine composition for the treatment of flu and preparation method thereof | |
| CN105078934A (en) | New application of piceatannol | |
| CN108066758B (en) | Raccoon dog canine distemper-parvovirus enteritis bigeminal live vaccine and preparation method and application thereof | |
| CN101254224A (en) | Green prune extract of anti acquired immuno-deficiency syndrome and bacterium | |
| CN106309455B (en) | The purposes of Peimisine | |
| US20170080035A1 (en) | Pharmaceutical composition for treating rotavirus and/or respiratory syncytial virus infection and method for preparing the same | |
| US20030054047A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
| CN104274497B (en) | Application of Taiwan cordyceps extract in preparing anti-respiratory virus medicine | |
| TWI541018B (en) | Taiwan Cordyceps extract for the manufacture of anti-respiratory virus drugs | |
| CN106344549B (en) | Application of the Rhein in preparation prevention and/or treatment hand-foot-and-mouth disease drug | |
| Odimegwu | Low-dose Sekikaic acid modulates host immunity and protects cells from Respiratory Syncytial Virus infection | |
| US11246898B2 (en) | Antiviral arthrospira maxima extract | |
| CN106957826B (en) | Virus inactivating agent and application thereof | |
| CN110917287A (en) | A medicinal plant extract | |
| CN104758340B (en) | Coffee mesitoyl quinine acid extract and its preparation method and application in a kind of folium lonicerae | |
| CN111568917B (en) | Application of flammulina velutipes polysaccharide extract in preparation of antiviral drugs and extraction method thereof | |
| JP7544801B2 (en) | Cyanobacterial extracts, methods for their preparation and use | |
| CN105943540A (en) | Application of simiarenol | |
| CN117643595A (en) | Composite polysaccharide and application thereof | |
| CN102727577A (en) | Medicinal composition for treating gynecological inflammations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191220 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |